pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Weekly maintenance dose of vitamin K antagonists (VKAs) according to ABCB1 C3435T polymorphism

Study Note Type of VKAs Maintenance dose (mg/week)

TT type CT type CC type

Mean N Mean N Mean N
Campos EIF et al. 2018 - Warfarin 29.9 ± 18.9 24 28.3 ± 12.5 57 33.0 ± 15.8 55
de Oliveira Almeida VC et al. 2014 - Warfarin 55.8 ± 38.3 54 45.5 ± 28.7 46 39.7 ± 26.6 16
Issac MS et al. 2014 - Warfarin 49 [28-54.30] 13 42 [35-49] 46 35 [28-45.50] 25
Kim Y et al. 2013 European Americans Warfarin 55.57 ± 14.20 23 60.14 ± 17.76 35 58.58 ± 14.25 16
African Americans 65.92 ± 22.18 6 58.45 ± 16.01 18 64.68 ± 21.03 35
Hispanic Americans 50.75 ± 6.06 4 53.16 ± 15.44 26 51.63 ± 12.04 12
Asian Americans 42.00 ± 0.0 3 52.85 ± 5.82 11 49.00 ± 5.35 7
Total 55.63 ± 15.39 36 56.94 ± 15.91 90 59.48 ± 17.98 70
Li W et al. 2020 - Warfarin 17.01 ± 5.6 29 18.69 ± 6.51 100 20.72 ± 8.89 85
Tavares LC et al. 2018 Caucasian Warfarin 26.8 ± 0.7 (SE) 44 27.3 ± 0.6 (SE) 115 30.0 ± 0.7 (SE) 74
non-Caucasian 25.1 ± 2.0 (SE)* 14 29.88 ± 1.0 (SE)* 38 35.3 ± 1.3 (SE)* 24
Total 26.2 ± 0.6 (SE)* 58 28.0 ± 0.5 (SE)* 153 30.5 ± 0.6 (SE)* 98
Gschwind L et al. 2015 - Acenocoumarol 16.17 ± 8.46 22 14.77 ± 5.11 57 13.72 ± 4.90 36
Jiménez-Varo E et al. 2014 Algorithm cohort Acenocoumarol 15 [11-19] 31 13 [10-18] 67 12 [8-18] 36
Saraeva RB et al. 2007 ≤7 mg/week, n (%)
7-28 mg/week, n (%)
≥28 mg/week, n (%)
Acenocoumarol 1 (6.3)
9 (56.3)
6 (37.5)
16 8 (15.7)
34 (66.7)
9 (17.6)
51 5 (17.2)
20 (69.0)
4 (13.8)
29
Sychev DA et al. 2016 - Acenocoumarol 21.7 ± 6.02 15 18.48 ± 7.07 25 24.15 ± 9.38 10

haplotype study; *p<0.05; VKAs=vitamin K antagonists; presented as mean ± standard deviation (SD) or median [range]; SE=standard error

Korean J Clin Pharm 2022;32:238-50 https://doi.org/10.24304/kjcp.2022.32.3.238
© 2022 Korean J Clin Pharm